317 results on '"Kobayashi, Kazufumi"'
Search Results
2. Clinical risk factors for portal hypertension-related complications in systemic therapy for hepatocellular carcinoma
3. Design and performance of the Climate Change Initiative Biomass global retrieval algorithm
4. Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective Analysis
5. Phase Ib trial of durvalumab plus tremelimumab in combination with particle therapy in patients with advanced hepatocellular carcinoma with macrovascular invasion: DEPARTURE trial.
6. Potential of circulating receptor-interacting protein kinase 3 levels as a marker of acute liver injury
7. Estimation of the effect of atezolizumab plus bevacizumab on pulmonary arterial hypertension using computed tomography in HCC patients
8. Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma
9. Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice
10. A diet-induced murine model for non-alcoholic fatty liver disease with obesity and insulin resistance that rapidly develops steatohepatitis and fibrosis
11. Liver biopsy technique in the era of genomic cancer therapies: a single-center retrospective analysis
12. The efficacy of contrast-enhanced computed tomography on the management of gastroesophageal varices in patients with hepatocellular carcinoma
13. SAT-335 Pathological dynamics and clinical implications of hepatitis in cancer patients undergoing immune checkpoint inhibitor
14. Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents
15. Assessment of Macrovascular Invasion in Advanced Hepatocellular Carcinoma: Clinical Implications and Treatment Outcomes with Systemic Therapy
16. EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma
17. The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma
18. Phase Ib trial of durvalumab plus tremelimumab in combination with particle therapy in advanced hepatocellular carcinoma patients with macrovascular invasion: DEPARTURE trial.
19. Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan
20. O138 / #126 - PHASE IB TRIAL OF DURVALUMAB PLUS TREMELIMUMAB WITH PARTICLE THERAPY FOR ADVANCED HCC: DEPARTURE
21. A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
22. Next-generation L-band SAR forest monitoring for highly accurate, operational deforestation early warning
23. Situation of hepatitis virus tests and measures to link test-positive individuals to specialists: a survey of institutions in Chiba, Japan, specializing in liver diseases
24. Histology-Based Assessment of Sonazoid-Enhanced Ultrasonography for the Diagnosis of Liver Metastasis
25. A 38-year (1978–2015) Northern Hemisphere daily snow cover extent product derived using consistent objective criteria from satellite-borne optical sensors
26. Application of transcutaneous ultrasonography for the diagnosis of muscle mass loss in patients with liver cirrhosis
27. Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment
28. Non-Invasive Diagnosis of Portal Hypertensive Gastropathy: Quantitative Analysis of Microbubble-Induced Stomach Wall Enhancement
29. Free fatty acid-based low-impedance liver image: a characteristic appearance in nonalcoholic steatohepatitis (NASH)
30. Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma
31. Impact of skeletal muscle volume on patients with BCLC stage‐B hepatocellular carcinoma undergoing sorafenib therapy
32. Exploration of new positions for cabozantinib for advanced hepatocellular carcinoma in the latest real-world practice
33. Successful Identification of a Novel Therapeutic Compound for Hepatocellular Carcinoma Through Screening of ADAM9 Inhibitors
34. A prospective study exploring the safety and efficacy of lenvatinib for patients with advanced hepatocellular carcinoma potential in current real-world practice.
35. Miglustat, a glucosylceramide synthase inhibitor, mitigates liver fibrosis through TGF-β/Smad pathway suppression in hepatic stellate cells
36. Left gastric vein-based noninvasive test for esophageal varices: a same-day comparison of portal hemodynamic assessment with endoscopic appearance
37. Comprehensive Analysis of Radiologic Cancer-Free Status through Various Treatment Approaches in Advanced-Stage Hepatocellular Carcinoma
38. Controlling Major Portal Vein Invasion Progression during Lenvatinib Treatment by Carbon-Ion Radiotherapy in Patients with Advanced Hepatocellular Carcinoma
39. Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real‐world practice
40. Antiviral Compounds Screening Targeting HBx Protein of the Hepatitis B Virus
41. Analysis of hyperprogressive disease due to atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma
42. Carbon‐ion radiotherapy versus radiofrequency ablation as initial treatment for early‐stage hepatocellular carcinoma
43. A case of hepatocellular carcinoma followed by asynchronous metastasis to the lung and thoracic spine following radical ablation treatment
44. Real‐world outcomes of molecular targeted agents for patients with hepatocellular carcinoma over 80 years old
45. Selective instance segmentation for pose estimation
46. Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma
47. Advancements in Global Forest Monitoring Research Founded on ALOS-2 Long-Term Pantropical Land Observation
48. Update of ALOS-3 Calibration and Validation Preparation Status
49. Risk prediction of hepatic encephalopathy after molecular targeted therapy for hepatocellular carcinoma in patients with cirrhosis
50. MO5-1 Regorafenib in advanced HCC patients who were not included in the RESORCE trial: first interim analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.